Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7162 + Pembrolizumab in Advanced Solid Tumors
NCT03364049Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of MK-7162 in solid tumor (4 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicities at Cycle 2, Adverse Events up to 27 months and 1 more. Started Dec 2017; status: completed.
02
Drugs
MK-7162
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03364049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03364049.